Evaluation of the Efficacy of Tenofovir in Chronic Hepatitis B Patients Unresponsive to Lamivudine

KAYHAN, Yusuf; DEMİR, ALİ; CIFCI, Sami; ASİL, Mehmet; biyik, murat; ATASEVEN, Hüseyin; GÜNGÖR, Gökhan

Evaluation of the Efficacy of Tenofovir in Chronic Hepatitis B Patients Unresponsive to Lamivudine

Sami CIFCI, (Necmettin Erbakan Üniversitesi, Meram Tıp Fakültesi, Gastroenteroloji Bölümü, Konya, Türkiye)

Yusuf KAYHAN, (Amasya Üniversitesi, Sabuncuoğlu Şerefeddin Eğitim ve Araştırma Hastanesi, Gastroenteroloji Kliniği, Amasya, Türkiye)

Gökhan GÜNGÖR, (Konya Eğitim ve Araştırma Hastanesi, Gastroenteroloji Kliniği, Konya, Türkiye)

Murat BIYIK, (Necmettin Erbakan Üniversitesi, Meram Tıp Fakültesi, Gastroenteroloji Bölümü, Konya, Türkiye)

Mehmet ASİL, (Necmettin Erbakan Üniversitesi, Meram Tıp Fakültesi, Gastroenteroloji Bölümü, Konya, Türkiye)

Hüseyin ATASEVEN, (Necmettin Erbakan Üniversitesi, Meram Tıp Fakültesi, Gastroenteroloji Bölümü, Konya, Türkiye)

Ali DEMİR (Necmettin Erbakan Üniversitesi, Meram Tıp Fakültesi, Gastroenteroloji Bölümü, Konya, Türkiye)

Viral Hepatitis Journal

1 1

Yıl: 2015 Cilt: 21 Sayı: 3 Sayfa Aralığı: 85 - 88 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Evaluation of the Efficacy of Tenofovir in Chronic Hepatitis B Patients Unresponsive to Lamivudine

Öz:

Amaç: Kronik hepatit B virüs (HBV) enfeksiyonu global bir sağlık problemi olup artmış morbidite ve mortalite ile ilişkilidir. Tedavideki ana hedef HBV replikasyonunu sürekli bir şekilde baskılayabilmektir. Ancak antiviral direnç kalıcı supresyon önünde ciddi bir engel teşkil etmektedir. Ülkemizde lamivude yanıtsız hastalarda tenofovire olan yanıtının değerlendirilmesi ile ilgili yeterli verilerin olmaması nedeniyle, bu çalışmanın yapılması planlanmıştır.Gereç ve Yöntemler: On sekiz yaşından büyük, en az 6 ay lamuvudin kullanmış ve direnç tespit edildikten sonra tenofovir başlanmış 48 hasta çalışmaya alındı. Hastaların tenofovir öncesi ve sonrası HBV DNA düzeyleri, hepatit B e antijen (HBeAg) serokonversiyonu ve hepatit B yüzey antijeni (HBsAg) kaybı oranları retrospektif olarak incelendi.Bulgular: Lamivudin direnci sonrası tenofovir alan hastalarda viral supresyon (HBV DNA <400 kopya/ml) tedavinin 6. ayında %89, 12. ayında %94 ve ortalama 21,4 aylık tedavi sonrası ise %96 oranında saptandı. Alanin aminotransferaz normalizasyonunun tedavinin birinci yılında %60 ve 21,4 aylık izlem süresinin sonunda ise %90 oranında sağlandığı görüldü. Tedavinin birinci yılında HBeAg kaybı %42 hastada tespit edildi. HBsAg kaybı izlem periyodu boyunca hiçbir hastada saptanmadı.Sonuç: Lamivudine yanıtsız kronik hepatit B hastalarında tenofovir etkili ve iyi tolere edilebilen bir tedavi seçeneğidir.

Anahtar Kelime:

Konular: Gastroenteroloji ve Hepatoloji

Lamivudine Yanıtsız Kronik Hepatit B Hastalarında Tenofovir Cevabının Değerlendirilmesi

Öz:

Objective: Chronic hepatitis B virus (HBV) infection is a global health problem and persistent viremia is associated with increased morbidity and mortality. The main goal of hepatitis B treatment is to suppress HBV replication permanently and, antiviral resistance is a major problem against viral suppression. Tenofovir is a potent antiviral drug with no reported resistance so far. There are inadequate data regarding response to tenofovir in chronic hepatitis B patients with lamivudine failure in Turkish population. The present study was conducted to evaluate response of tenofovir in patients with lamivudine failure.Materials and Methods: A total of 48 adult patients with chronic hepatitis B, who have received lamivudine for at least 6 months and switched to tenofovir due to lamivudine failure were investigated retrospectively. HBV DNA levels, alanine aminotransferase (ALT) levels and serum creatinine levels were evaluated before and after tenofovir treatment and also hepatitis B e antigen (HBeAg) seroconversion and hepatitis B surface antigen (HBsAg) loss rates were evaluated.Results: Viral suppression rates (HBV DNA <400 copies/ml) were found to be 89% on the 6th month and 94% on the 12th month of tenofovir treatment. The mean follow-up time was 21.4 months and totally 96% of patients were found to achieve viral suppression with tenofovir. ALT normalization rates were found to be 60% on the first year of treatment with tenofovir and overall ALT normalization rate was 90%. HBeAg seroconversion was detected in 42% of HBe antigen (+) patients after the first year of tenofovir treatment and disappearance of HBsAg was observed in none of the patients.Conclusion: Tenofovir treatment is an effective and well-tolerated therapeutic option in chronic hepatitis B resistant to lamivudine.

Anahtar Kelime:

Konular: Gastroenteroloji ve Hepatoloji

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

Kao JH, Chen DS. Global control of hepatitis B virus infection. Lancet Infect Dis. 2002;2(7):395-403.
Tozun N, Ozdogan O, Çakaloğlu Y, Idilman R, Karasu Z, Akarca U et al. Nationwide Prevalence Study and Risk Factors for Hepatitis A, B, C and D Infections in Turkey. The 61st Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting® 2010. October 29- November 2 2010, Boston USA, Poster No: 789, Hepatology Vol 52 S1:697 A.
Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, Dienstag JL, Heathcote EJ, Little NR, Griffiths DA, Gardner SD, Castiglia M. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology. 2003;125(6):1714-1722.
Marcellin P, Chang TT, Lim SG, Sievert W, Tong M, Arterburn S, Borroto-Esoda K, Frederick D, Rousseau F. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology. 2008;48:750- 758.
Liaw YF1, Gane E, Leung N, Zeuzem S, Wang Y, Lai CL, Heathcote EJ, Manns M, Bzowej N, Niu J, Han SH, Hwang SG, Cakaloglu Y, Tong MJ, Papatheodoridis G, Chen Y, Brown NA, Albanis E, Galil K, Naoumov NV; GLOBE Study Group. 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology. 2009;136(2):486-495.
Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, Wichroski MJ, Xu D, Yang J, Wilber RB, Colonno RJ. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology. 2009;49(5):1503-1514.
Kitrinos KM, Corsa A, Liu Y, Flaherty J, Snow-Lampart A, Marcellin P, Borroto-Esoda K, Miller MD. No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. Hepatology. 2014;59(2):434-442.
European Association For The Study Of The L. EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012;57(1):167-185.
Idilman R, Gunsar F, Koruk M, Keskin O, Meral CE, Gulsen M, Elhan AH, Akarca US, Yurdaydin C. Long-term entecavir or tenofovir disoproxil fumarate therapy in treatment-naïve chronic hepatitis B patients in the real-world setting. J Viral Hepat. 2015;22(5):504-510.
Kuo A, Dienstag JL, Chung RT. Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B. Clin Gastroenterol Hepatol. 2004;2(3):266-272.
Baran B, Soyer OM, Ormeci AC, Gokturk S, Evirgen S, Bozbey HU, Akyuz F, Karaca C, Demir K, Besisik F, Onel D, Gulluoglu M, Badur S, Kaymakoglu S. Efficacy of tenofovir in patients with Lamivudine failure is not different from that in nucleoside/ nucleotide analogue-naive patients with chronic hepatitis B. Antimicrob Agents Chemother. 2013;57(4):1790-1796.
Basarır I, Ilikhan S, Harmandar F, Soyaltın UE, Aydemir S, Ustundag Y. Assessment of treatment responses in patients with chronic active hepatitis B. Akademik Gastroenteroloji Dergisi 2013:12(2):58-65.
Van Bommel F, de Man RA, Wedermeyer H, Deterding K, Petersen J, Buggisch P, Erhardt A, Hüppe D, Stein K, Trojan J, Sarrazin C, Böcher WO, Spengler U, Wasmuth HE, Reinders JG, Möller B, Rhode P, Feucht HH, Wiedenmann B, Berg T. Long- term efficacy of tenofovir monotherapy for hepatitis B virus- monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology. 2010;51(1):73-80.
Antoniou T, Raboud J, Chirhin S, Yoong D, Govan V, Gough K, Rachlis A, Loutfy M. Incidence of and risk factors for tenofovir- induced nephrotoxicity: a retrospective cohort study. HIV Med. 2005;6(4):284-290.
Khungar V, Han SH. A Systematic Review of Side Effect of Nucleoside and Nucleotide Drugs Used for Treatment of Chronic Hepatitis B. Curr Hepat Rep. 2010;9(2):75-90.

APA	CIFCI S, KAYHAN Y, GÜNGÖR G, biyik m, ASİL M, ATASEVEN H, DEMİR A (2015). Evaluation of the Efficacy of Tenofovir in Chronic Hepatitis B Patients Unresponsive to Lamivudine. , 85 - 88.
Chicago	CIFCI Sami,KAYHAN Yusuf,GÜNGÖR Gökhan,biyik murat,ASİL Mehmet,ATASEVEN Hüseyin,DEMİR ALİ Evaluation of the Efficacy of Tenofovir in Chronic Hepatitis B Patients Unresponsive to Lamivudine. (2015): 85 - 88.
MLA	CIFCI Sami,KAYHAN Yusuf,GÜNGÖR Gökhan,biyik murat,ASİL Mehmet,ATASEVEN Hüseyin,DEMİR ALİ Evaluation of the Efficacy of Tenofovir in Chronic Hepatitis B Patients Unresponsive to Lamivudine. , 2015, ss.85 - 88.
AMA	CIFCI S,KAYHAN Y,GÜNGÖR G,biyik m,ASİL M,ATASEVEN H,DEMİR A Evaluation of the Efficacy of Tenofovir in Chronic Hepatitis B Patients Unresponsive to Lamivudine. . 2015; 85 - 88.
Vancouver	CIFCI S,KAYHAN Y,GÜNGÖR G,biyik m,ASİL M,ATASEVEN H,DEMİR A Evaluation of the Efficacy of Tenofovir in Chronic Hepatitis B Patients Unresponsive to Lamivudine. . 2015; 85 - 88.
IEEE	CIFCI S,KAYHAN Y,GÜNGÖR G,biyik m,ASİL M,ATASEVEN H,DEMİR A "Evaluation of the Efficacy of Tenofovir in Chronic Hepatitis B Patients Unresponsive to Lamivudine." , ss.85 - 88, 2015.
ISNAD	CIFCI, Sami vd. "Evaluation of the Efficacy of Tenofovir in Chronic Hepatitis B Patients Unresponsive to Lamivudine". (2015), 85-88.

APA	CIFCI S, KAYHAN Y, GÜNGÖR G, biyik m, ASİL M, ATASEVEN H, DEMİR A (2015). Evaluation of the Efficacy of Tenofovir in Chronic Hepatitis B Patients Unresponsive to Lamivudine. Viral Hepatitis Journal, 21(3), 85 - 88.
Chicago	CIFCI Sami,KAYHAN Yusuf,GÜNGÖR Gökhan,biyik murat,ASİL Mehmet,ATASEVEN Hüseyin,DEMİR ALİ Evaluation of the Efficacy of Tenofovir in Chronic Hepatitis B Patients Unresponsive to Lamivudine. Viral Hepatitis Journal 21, no.3 (2015): 85 - 88.
MLA	CIFCI Sami,KAYHAN Yusuf,GÜNGÖR Gökhan,biyik murat,ASİL Mehmet,ATASEVEN Hüseyin,DEMİR ALİ Evaluation of the Efficacy of Tenofovir in Chronic Hepatitis B Patients Unresponsive to Lamivudine. Viral Hepatitis Journal, vol.21, no.3, 2015, ss.85 - 88.
AMA	CIFCI S,KAYHAN Y,GÜNGÖR G,biyik m,ASİL M,ATASEVEN H,DEMİR A Evaluation of the Efficacy of Tenofovir in Chronic Hepatitis B Patients Unresponsive to Lamivudine. Viral Hepatitis Journal. 2015; 21(3): 85 - 88.
Vancouver	CIFCI S,KAYHAN Y,GÜNGÖR G,biyik m,ASİL M,ATASEVEN H,DEMİR A Evaluation of the Efficacy of Tenofovir in Chronic Hepatitis B Patients Unresponsive to Lamivudine. Viral Hepatitis Journal. 2015; 21(3): 85 - 88.
IEEE	CIFCI S,KAYHAN Y,GÜNGÖR G,biyik m,ASİL M,ATASEVEN H,DEMİR A "Evaluation of the Efficacy of Tenofovir in Chronic Hepatitis B Patients Unresponsive to Lamivudine." Viral Hepatitis Journal, 21, ss.85 - 88, 2015.
ISNAD	CIFCI, Sami vd. "Evaluation of the Efficacy of Tenofovir in Chronic Hepatitis B Patients Unresponsive to Lamivudine". Viral Hepatitis Journal 21/3 (2015), 85-88.